US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

8.950 +0.010 (+0.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date ↗
Via Chartmill
Capricor Therapeutics Inc (NASDAQ:CAPR) Reports Q4 2025 Loss, Focus Remains on FDA Review for Deramiocel ↗
Via Chartmill
News headline image
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
From Johnson Fistel, PLLP
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz 
Via Business Wire
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? ↗
Focused on rare disease therapeutics, this biotech firm reported a notable insider sale amid a year of substantial stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy ↗
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its... 
Via MarketBeat
News headline image
Capricor (CAPR) Q1 2026 Earnings Transcript ↗
Capricor (CAPR) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Capricor Therapeutics Q1 Earnings Call Highlights ↗
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself... 
Via MarketBeat
Topics Earnings
News headline image
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval. 
Via Stocktwits
Topics Earnings
News headline image
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval ↗
The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 
Via Stocktwits
Topics Earnings
News headline image
Capricor (CAPR) Q4 2025 Earnings Call Transcript ↗
Capricor (CAPR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy ↗
For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024. 
Via Stocktwits
News headline image
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures ↗
The update comes as the therapy’s regulatory application awaits a decision from the U.S. Food and Drug Administration later this year. 
Via Stocktwits
News headline image
CAPR Stock Surged 17% Today — What’s Fueling The Rally? ↗
The FDA has lifted a previous Complete Response Letter and resumed review of the company’s Biologics License Application for Deramiocel. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >